MCK vs RMTI vs SKYA Stock Comparison

Mckesson, Rockwell Medical and SkyAI Prices as of Nov 3, 2026 Peers: Industry group
1 more company in this comparison (CAH) Create a free account to keep reading and compare up to 10 companies.
MCK Mckesson Corp
$999.91 +10.7% 1M +21.9% 1Y
Market cap
$126.38B
P/E
27.5x
Revenue (TTM)
$410.98B
Div. yield
0.00%
Drug Distribution Healthcare
6 wins
RMTI Rockwell Medical, Inc.
$8.09 -5.4% 1M +649.1% 1Y
Market cap
$31.63M
P/E
–
Revenue (TTM)
$69.39M
Div. yield
–
Medical Supplies Healthcare
1 win
SKYA SkyAI, Inc.
$2.95 +60.3% 1M -31.1% 1Y
Market cap
$212.68M
P/E
–
Revenue (TTM)
$174.18K
Div. yield
–
Medical Supplies Healthcare
2 wins

Head to Head

9 decided of 12

Mckesson leads on 6 of the 12 questions below (Mckesson 6, SkyAI 2, Rockwell Medical 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionMCKRMTISKYALeader
Larger companyMarket capitalisation $126.38B $31.63M $212.68M MCK
Cheaper on earningsLower P/E, profitable companies only 27.5x -6.2x -0.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.2x — 0.0x SKYA
Faster revenue growthRevenue growth, trailing twelve months +8.8% -21.1% +108.0% SKYA
More profitableNet margin, trailing twelve months 1.1% -7.3% -228,220.7% MCK
Better return on capitalReturn on invested capital 107.9% — — –
Less leveragedLower net debt / EBITDA 0.6x 7.8x — MCK
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +21.9% +649.1% -31.1% RMTI
Better 5-year returnAnnualised price return, 5 years +35.0%/yr +6.0%/yr — MCK
Less volatileAnnualised volatility, 1 year 30.7% 402.1% 105.3% MCK
Higher overall scoreMean of the five percentile scores vs peers 60/100 57/100 27/100 MCK

Percentile Scorecard

MCKRMTISKYA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisMCKRMTISKYA
Valuation 52 #13 of 26 89 #26 of 229 4 #220 of 229
Growth 63 #10 of 25 26 #164 of 221 4 #212 of 221
Profitability 67 #9 of 25 56 #93 of 209 1 #208 of 209
Financial Health 48 #14 of 26 56 #107 of 240 95 #13 of 240
Shareholder Returns 69 #6 of 17 – 34 #98 of 147
Overall 60 57 27
  • MCK ranked among 27 companies in Healthcare Payers and Distributors
  • RMTI ranked among 248 companies in Medical Devices and Diagnostics
  • SKYA ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodMCKRMTISKYASPY
1 month +10.7%-5.4%+60.3% -2.0%
3 months +20.4%+6.9%+126.9% -2.2%
6 months +24.8%+840.7%+55.3% +4.2%
Year to date +21.9%+874.7%+45.3% +10.6%
1 year +21.9%+649.1%-31.1% +10.4%
3 years +120.8%+290.8%-99.9% +73.6%
3 years, per year +30.2%+57.6%-90.0% +20.2%
5 years +348.2%+33.7%— +61.6%
5 years, per year +35.0%+6.0%— +10.1%
10 years +671.6%-86.6%— +261.3%
10 years, per year +22.7%-18.2%— +13.7%

Risk

MeasureMCKRMTISKYASPY
Volatility, 1Y 30.7%402.1%105.3% 12.8%
Downside volatility, 1Y 27.4%354.5%104.8% 12.8%
Beta vs S&P 500, 1Y -0.271.712.49 1.00
Return / volatility, 1Y 0.711.61-0.30 0.81
Max drawdown, 5Y -27.2%-91.1%-100.0% -25.4%
From 52-week high -2.9%-8.6%-31.1% -3.2%
52-week high $1,030.18$8.85$4.28 $779.14
52-week low $725.17$0.55$0.95 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleMCKRMTISKYA
P/E now vs peer median 25.8xmedian 23.9x -6.3xmedian 28.1x -0.5xmedian 28.1x
P/S now vs peer median 0.3xmedian 0.3x 0.5xmedian 2.9x 1,221xmedian 2.9x
EV/EBITDA now vs peer median 16.7xmedian 13.4x -8.1xmedian 18.0x -0.5xmedian 18.0x
P/FCF now vs peer median 18.2xmedian 16.0x 21.4xmedian 24.8x -1.1xmedian 24.8x
P/B now vs peer median -27.5xmedian 2.5x 0.9xmedian 2.3x 1.4xmedian 2.3x
PEG now vs peer median 2.16median 1.61 -0.15median 0.95 0.01median 0.95

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsMCKRMTISKYA
Revenue $410.98B $69.39M $174.18K
Gross profit $14.96B $12.29M $324.68K
Operating income $6.50B -$4.52M -$374.36M
Net income $5.30B -$5.08M -$397.51M
Free cash flow $6.42B $1.50M -$201.93M
R&D – $40.00K $475.55K
EPS (diluted) $38.52 $-1.28 $-5.51
Cash & equivalents $5.16B $10.52M $12.07M
Total debt $9.73B $9.00M –
Shares (diluted) 119.20M 3.96M 72.09M
Enterprise value $110.28B -$65.76M $167.38M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricMCKRMTISKYA
P/E 25.8x -6.3x -0.5x
P/FCF 18.2x 21.4x -1.1x
P/Operating cash flow 17.0x 11.3x -14.8x
P/S 0.3x 0.5x 1,221x
P/B -27.5x 0.9x 1.4x
P/Tangible book -14.1x 1.3x 16.4x
EV/EBITDA 16.7x -8.1x -0.5x
EV/EBIT 18.7x -3.6x -0.5x
EV/Revenue 0.3x 0.2x 1,152x
EV/FCF 18.9x 10.9x -1.0x
EV/Operating cash flow 17.7x 5.7x -13.9x
PEG (3Y EPS CAGR) 2.16 -0.15 0.01

Growth

14 metrics
MetricMCKRMTISKYA
Revenue growth (1Y) 8.8% -21.1% 108.0%
Revenue CAGR (3Y) 13.1% -2.9% 19.4%
Gross profit growth (1Y) 11.2% -20.3% –
Gross profit CAGR (3Y) 6.6% 22.1% –
Operating income growth (1Y) 46.6% -250.1% -8,055%
Operating income CAGR (3Y) 13.5% 23.4% -240.7%
Net income growth (1Y) 58.1% -142.2% -54,854%
Net income CAGR (3Y) 10.7% 24.1% -268.2%
EPS growth (1Y) 52.8% -109.9% -658.6%
EPS CAGR (3Y) 12.0% 41.1% -100.6%
Operating cash flow growth (1Y) 4.7% -18.3% -356.8%
Operating cash flow CAGR (3Y) 10.7% 34.2% -24.4%
Free cash flow growth (1Y) 6.8% -44.2% -6,031%
Free cash flow CAGR (3Y) 11.3% 30.2% -196.9%

Profitability

14 metrics
MetricMCKRMTISKYA
Gross margin 3.6% 17.7% 186.4%
EBITDA margin 1.8% -2.9% -214,892%
Operating margin 1.6% -6.5% -214,931%
Pretax margin 1.6% -7.9% -221,236%
Net margin 1.1% -7.3% -228,221%
FCF margin 1.6% 2.2% -115,934%
Operating cash flow margin 1.7% 4.1% -8,259%
Return on equity – -15.5% -280.7%
Return on assets 6.2% -9.6% -276.3%
Return on invested capital 107.9% – –
Return on capital employed 43.4% -9.9% -223.1%
Asset turnover 4.8x 1.2x 0.0x
Cash conversion (OCF / net income) 1.3x -0.6x 0.0x
Stock comp / revenue – 2.7% 52,451%

Financial Health

11 metrics
MetricMCKRMTISKYA
Debt / assets 11.0% 15.9% –
Debt / equity -2.3x 0.3x –
Net debt / EBITDA 0.6x 7.8x –
Debt / FCF 1.5x 6.0x –
Liabilities / assets 104.8% 37.9% 1.9%
Equity / assets -4.8% 62.1% 98.1%
Interest coverage 23.6x -4.0x –
Current ratio 0.9x 3.3x 5.3x
Quick ratio 0.5x 3.0x 4.4x
Cash ratio 0.1x 2.2x 4.2x
Altman Z-score 5.91 -7.65 30.23

Shareholder Returns

7 metrics
MetricMCKRMTISKYA
Dividend yield 0.3% – –
Net buyback yield 5.7% – -0.6%
Shareholder yield 6.0% – -0.6%
Payout ratio (earnings) 7.4% – –
Payout ratio (FCF) 6.1% – –
Dividend growth (1Y) 11.3% – –
Dividend CAGR (3Y) 10.0% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusMCKRMTISKYA
Forward P/E 21.2xFY2026 – 0.0xFY2026
EPS, next fiscal year $47.15FY2026 $-0.97FY2026 $2,362.06FY2026
EPS growth, next FY +20.6%FY2026 – –
EPS growth, the year after +11.0% – –
Revenue, next fiscal year $444.47BFY2026 $77.07MFY2026 $70.01MFY2026
Revenue growth, next FY +10.2%FY2026 +11.3%FY2026 +34,200.1%FY2026
Revenue growth, the year after +1.5% +7.5% +17.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersMCKRMTISKYA
Held by institutions 89.1% 8.6% –
Institutions holding 2,014 33 –
Change in shares held, QoQ -0.7% -14.2% –
Institutions buying 883 13 –
Institutions selling 793 9 –
Buyers to sellers 1.11 1.44 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

MCKRMTISKYA
MCK 1.00 -0.03 -0.10
RMTI -0.03 1.00 0.04
SKYA -0.10 0.04 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, MCK, RMTI and SKYA?

Mckesson (MCK) is the largest by market capitalisation: Mckesson (MCK) $126.38B, Rockwell Medical (RMTI) $31.63M, SkyAI (SKYA) $212.68M.

Which company is growing faster?

SkyAI (SKYA) grew revenue fastest over the trailing twelve months: Mckesson (MCK) +8.8%, Rockwell Medical (RMTI) -21.1%, SkyAI (SKYA) +108.0%.

Which company is more profitable?

Mckesson (MCK) has the highest net margin (Mckesson (MCK) 1.1%, Rockwell Medical (RMTI) -7.3%, SkyAI (SKYA) -228,220.7%).

Which stock has performed better?

Over the past year Rockwell Medical (RMTI) returned the most: Mckesson (MCK) +21.9%, Rockwell Medical (RMTI) +649.1%, SkyAI (SKYA) -31.1%. Over five years, Mckesson (MCK) compounded fastest (Mckesson (MCK) +35.0%/yr, Rockwell Medical (RMTI) +6.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Mckesson (MCK) 0.00%, Rockwell Medical (RMTI) 0.00%, SkyAI (SKYA) 0.00%. Rockwell Medical (RMTI) and SkyAI (SKYA) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Mckesson (MCK) has been the steadiest (Mckesson (MCK) 30.7%, Rockwell Medical (RMTI) 402.1%, SkyAI (SKYA) 105.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, MCK, RMTI and SKYA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Mckesson (MCK) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.